In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease.
The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.
In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.
Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.
From the outside looking in, these Alzheimer’s drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?
To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, and co-director of the Penn Memory Center.
Transcripts for each segment will be available after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
731: A Strange-Looking Fish, Frozen In Time
732: What We Know After 4 Years Of COVID-19
733: Science Unlocks The Power Of Flavor In ‘Flavorama’
729: Abortion-Restrictive States Leave Ob-Gyns With Tough Choices
730: Nasal Rising Safely | How Your Brain Constructs Your Mental Health
726: A New Book Puts ‘Math in Drag’
725: With This Rare Disorder, No Amount Of Sleep Is Enough
724: How Election Science Can Support Democracy | The Genetic Roots Of Antibiotic Resistance
728: Triple Feature: Dune, Mars, And An Alien On Earth
727: Could This Be The End Of Voyager 1?
723: What It Takes To Care For The US Nuclear Arsenal
722: A Young Scientist Uplifts The Needs Of Parkinson’s Patients
721: Snakes Are Evolutionary Superstars | Whale Song Is All In The Larynx
720: What’s Behind The Measles Outbreak In Florida?
719: Pythagoras Was Wrong About Music | Biochar's Potential For Carbon Capture
718: As Space Exploration Expands, So Will Space Law
717: Blood In The Water: Shark Smell Put To The Test
714: How Trivia Experts Recall Facts | One Ant Species Sent Ripples Through A Food Web
716: OpenAI’s New Product Makes Incredibly Realistic Fake Videos
715: Private Spacecraft Makes Historic Moon Landing | New Cloud Seeding Technique
Create your
podcast in
minutes
It is Free
The Modern West
Voices of Misery Podcast
House of Whimsical Terror
Dairyland Frights
Stuff You Should Know
Timcast IRL